AIA Group Ltd Increases Stock Position in Johnson & Johnson (NYSE:JNJ)

AIA Group Ltd boosted its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 89.2% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 49,552 shares of the company’s stock after purchasing an additional 23,356 shares during the quarter. AIA Group Ltd’s holdings in Johnson & Johnson were worth $8,796,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of JNJ. Vanguard Group Inc. increased its holdings in shares of Johnson & Johnson by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock worth $42,205,749,000 after buying an additional 3,358,478 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Johnson & Johnson by 0.4% in the 1st quarter. BlackRock Inc. now owns 200,799,189 shares of the company’s stock worth $35,587,638,000 after buying an additional 777,837 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Johnson & Johnson by 0.8% in the 1st quarter. Wellington Management Group LLP now owns 32,772,594 shares of the company’s stock worth $5,808,286,000 after buying an additional 265,330 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Johnson & Johnson by 1.6% in the 1st quarter. Bank of New York Mellon Corp now owns 32,070,396 shares of the company’s stock worth $5,683,837,000 after buying an additional 509,818 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after buying an additional 328,297 shares during the last quarter. Hedge funds and other institutional investors own 68.59% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 76,923 shares of the company’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider William Hait sold 15,000 shares of the stock in a transaction that occurred on Monday, October 24th. The shares were sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the completion of the sale, the insider now owns 80,236 shares of the company’s stock, valued at $13,764,485.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jennifer L. Taubert sold 76,923 shares of the stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the sale, the executive vice president now directly owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 212,646 shares of company stock valued at $36,791,022. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $177.01 on Thursday. The stock has a market cap of $462.79 billion, a price-to-earnings ratio of 24.65, a price-to-earnings-growth ratio of 3.49 and a beta of 0.57. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The firm has a 50-day moving average of $168.35 and a two-hundred day moving average of $171.28.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. During the same quarter in the prior year, the company earned $2.60 EPS. The company’s revenue was up 1.9% compared to the same quarter last year. On average, research analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson announced that its board has approved a share buyback plan on Wednesday, September 14th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the company to reacquire up to 1.2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be given a $1.13 dividend. The ex-dividend date is Monday, November 21st. This represents a $4.52 annualized dividend and a dividend yield of 2.55%. Johnson & Johnson’s payout ratio is presently 62.95%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research reports. Atlantic Securities reduced their target price on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Wednesday, October 19th. Raymond James cut their price target on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a report on Wednesday, October 19th. Bank of America cut their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Credit Suisse Group began coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target on the stock. Finally, Barclays began coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $181.33.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.